Goldman Sachs on Immunovant (IMVT): 'We view these data as compelling'
Tweet Send to a Friend
Goldman Sachs analyst Corinne Johnson reiterated a Buy rating and $50.00 price target on Immunovant (NASDAQ: IMVT).The analyst comments "IMVT ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
